Scholarlink

Purpose of Review <p>This review explores the evolving role of anti-obesity medications (AOMs) in managing cardiovascular (CV) risk among individuals with overweight and obesity. We discuss the current evidence supporting both traditional weight loss methods and emerging treatments, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists, for intentional weight loss and reduced CV risk.</p> Recent Findings <p>Results from CV outcomes trials have demonstrated the efficacy of GLP-1 RA and dual GLP-1/GIP receptor agonists to promote weight loss and improve CV outcomes across diverse populations, including reduced risk of major adverse CV events and mortality, progression of chronic kidney disease, as well as improvements in quality of life and functional status.</p> Summary <p>Current evidence supports the beneficial role of AOMs in reducing CV risk in selected high-risk individuals with overweight or obesity. Ongoing and future trials will be crucial to confirm these findings, attempt to uncouple GLP-1 RA-specific benefits from weight loss alone, refine the populations most likely to benefit for clinical management, and optimize treatment strategies. These developments hold promise for transforming CV risk management in the context of overweight and obesity and guiding future clinical practice and research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Obesity Management and Cardiovascular Risk Reduction: from Tradition to Innovation

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Thomaz Alexandre Costa,
  • Josephine Harrington,
  • Adam J. Nelson,
  • Ambarish Pandey,
  • Ian J. Neeland,
  • Matthew M. Y. Lee,
  • Yu Mi Kang,
  • Darren K. McGuire

摘要

Purpose of Review

This review explores the evolving role of anti-obesity medications (AOMs) in managing cardiovascular (CV) risk among individuals with overweight and obesity. We discuss the current evidence supporting both traditional weight loss methods and emerging treatments, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists, for intentional weight loss and reduced CV risk.

Recent Findings

Results from CV outcomes trials have demonstrated the efficacy of GLP-1 RA and dual GLP-1/GIP receptor agonists to promote weight loss and improve CV outcomes across diverse populations, including reduced risk of major adverse CV events and mortality, progression of chronic kidney disease, as well as improvements in quality of life and functional status.

Summary

Current evidence supports the beneficial role of AOMs in reducing CV risk in selected high-risk individuals with overweight or obesity. Ongoing and future trials will be crucial to confirm these findings, attempt to uncouple GLP-1 RA-specific benefits from weight loss alone, refine the populations most likely to benefit for clinical management, and optimize treatment strategies. These developments hold promise for transforming CV risk management in the context of overweight and obesity and guiding future clinical practice and research.